|
Jun 26
|
Is Precigen (NASDAQ:PGEN) In A Good Position To Invest In Growth?
|
|
Feb 6
|
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
|
Feb 4
|
Insider Stock Buying Reaches US$1.72m On Precigen
|
|
Jan 16
|
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
|
|
Dec 27
|
Even after rising 15% this past week, Precigen (NASDAQ:PGEN) shareholders are still down 86% over the past three years
|
|
Dec 18
|
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Nov 29
|
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
|
|
Sep 25
|
While institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 37% ownership
|
|
Aug 9
|
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
|
|
Aug 9
|
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
|